Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367045 | 1.00 | MAOA (0.51) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL3366821 | 0.83 | MAOA (0.49) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL3366827 | 0.83 | MAOA (0.49) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL7702609 | 0.77 | KDM4E (0.34) | MAOAMAOBKDM4EMAPTL3MBTL1 | |
| SCHEMBL7702607 | 0.77 | KDM4E (0.34) | MAOAMAOBKDM4EMAPTL3MBTL1 | |
| SCHEMBL3367085 | 0.75 | MAOA (0.62) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL3367097 | 0.75 | MAOA (0.62) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL6747962 | 0.72 | MAOA (0.50) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL6747958 | 0.72 | MAOA (0.50) | MAOAMAOBKCNH2LMNAHPGD | |
| SCHEMBL3366705 | 0.71 | MAOA (0.49) | MAOAMAOBKCNH2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706754-B2 | ANTIPROTOZOA AGENTS, PARASITICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-03-16 | — | — | US | claimed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | claimed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | claimed |
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | The University of North Carolina at Chapel Hill: | 2008-03-06 | — | — | US | disclosed |
| US-7241795-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-10 | — | — | US | disclosed |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| US-6737440-B2 | 2,5-BIS ((ALKYL (OR ARYL) IMINO) AMINOPHENYL) FURANS, THIOPHENES OR PYRROLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-05-18 | — | — | US | disclosed |
| US-6706754-B2 | ANTIPROTOZOA AGENTS, PARASITICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-03-16 | — | — | US | disclosed |
| EP-1337510-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC \"REVERSED AMIDINES\ | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | GEORGIA STATE UNIVERSITY | 2003-05-01 | — | — | US | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002057224-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC 'REVERSED AMIDINES' | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | HRH4, TLR7, DDAH1 | MAOA 2516/4885MAOB 2179/4885KCNH2 619/4885 |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | HRH4, HDHD5, MRPS7 | MAOA 2831/4885MAOB 2400/4885KCNH2 574/4885 |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | TLR7, DHRS9, TLR8 | MAOA 3329/4885MAOB 3223/4885KCNH2 1248/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | MAOA 1947/4885MAOB 1685/4885KCNH2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.